Elagolix reduced dyspareunia and improved health-related quality of life in premenopausal women with endometriosis-associated pain
article
OA: bronze
CC0
⤵ 3 in-corpus citations
AI-generated summary
Elagolix treatment in premenopausal women with endometriosis-associated pain led to reduced dyspareunia and improved health-related quality of life.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
My notes (saved in your browser only)
Condition tags
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cited by (3)
- Endometriosis: advances and controversies in classification, pathogenesis, diagnosis, and treatment 2019
- A systematic literature review on patient-reported outcome domains and measures in nonsurgical efficacy trials related to chronic pain associated with endometriosis: an urgent call to action 2024
- Elagolix in endometriosis-related pain: a profile of its use as approved in the USA 2019
Cited by (3)
- A systematic literature review on patient-reported outcome domains and measures in nonsurgical efficacy trials related to chronic pain associated with endometriosis: an urgent call to action 2024
- Elagolix in endometriosis-related pain: a profile of its use as approved in the USA 2019
- Endometriosis: advances and controversies in classification, pathogenesis, diagnosis, and treatment 2019
Source provenance
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0
· commercial use OK